RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and microRNA expression signatures

Journal of Clinical Oncology

Volumn 30, Issue 25, 2012, Pages 3109-3118

  Mendler, Jason H ^a   Maharry, Kati ^a,b   Radmacher, Michael D ^a,b   Mrózek, Krzysztof ^a   Becker, Heiko ^a   Metzeler, Klaus H ^a   Schwind, Sebastian ^a   Whitman, Susan P ^a   Khalife, Jihane ^a   Kohlschmidt, Jessica ^a,b   Nicolet, Deedra ^a,b   Powell, Bayard L ^c   Carter, Thomas H ^e   Wetzler, Meir ^f   Moore, Joseph O ^d   Kolitz, Jonathan E ^g   Baer, Maria R ^h   Carroll, Andrew J ⁱ   Larson, Richard A ^j   Caligiuri, Michael A ^a   Marcucci, Guido ^a   Bloomfield, Clara D ^a   more..

^a OHIO STATE UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

^g DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^h UNIVERSITY OF MARYLAND   (United States)

ⁱ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^j UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CADMIUM 109; CD135 ANTIGEN; CYTARABINE; DNA NUCLEOTIDYLEXOTRANSFERASE; FLT3 LIGAND; MICRORNA; MICRORNA 223; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; B LYMPHOCYTE; CANCER SURVIVAL; CYTOGENETICS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; EVENT FREE SURVIVAL; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; HEMATOPOIETIC CELL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MYELOPOIESIS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CORE BINDING FACTOR ALPHA 2 SUBUNIT; CYTOGENETIC ANALYSIS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; LOGISTIC MODELS; MALE; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; POLYMERASE CHAIN REACTION; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84865720625     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.6652     Document Type: Article

References (56)

1. Gaidzik V, Döhner K: Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. Semin Oncol 35:346-355, 2008
2. Mrózek K, Heerema NA, Bloomfield CD: Cytogenetics in acute leukemia. Blood Rev 18:115-136, 2004
3. Mrózek K, Marcucci G, Paschka P, et al: Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: Are we ready for a prognostically prioritized molecular classification? Blood 109:431-448, 2007
4. Thiede C, Steudel C, Mohr B, et al: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326-4335, 2002
5. Whitman SP, Archer KJ, Feng L, et al: Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A Cancer and Leukemia Group B study. Cancer Res 61:7233-7239, 2001
6. Döhner K, Schlenk RF, Habdank M, et al: Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations. Blood 106:3740-3746, 2005
7. Falini B, Mecucci C, Tiacci E, et al: Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352:254-266, 2005
8. Fröhling S, Schlenk RF, Stolze I, et al: CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: Prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22:624-633, 2004
9. Marcucci G, Maharry K, Radmacher MD, et al: Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: A Cancer and Leukemia Group B study. J Clin Oncol 26:5078-5087, 2008
10. Paschka P, Marcucci G, Ruppert AS, et al: Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 26:4595-4602, 2008
11. Virappane P, Gale R, Hills R, et al: Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 26:5429-5435, 2008
12. Caligiuri MA, Strout MP, Lawrence D, et al: Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res 58:55-59, 1998
13. Whitman SP, Ruppert AS, Marcucci G, et al: Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: A Cancer and Leukemia Group B study. Blood 109:5164-5167, 2007
14. Marcucci G, Maharry K, Wu YZ, et al: IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 28:2348-2355, 2010
15. Paschka P, Schlenk RF, Gaidzik VI, et al: IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 28:3636-3643, 2010
16. Metzeler KH, Maharry K, Radmacher MD, et al: TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 29:1373-1381, 2011
17. Döhner H, Estey EH, Amadori S, et al: Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453-474, 2010
18. Becker H, Marcucci G, Maharry K, et al: Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: A Cancer and Leukemia Group B study. J Clin Oncol 28:596-604, 2010
19. Okuda T, van Deursen J, Hiebert SW, et al: AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84:321-330, 1996
20. Michaud J, Wu F, Osato M, et al: In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: Implications for mechanisms of pathogenesis. Blood 99:1364-1372, 2002
21. Song WJ, Sullivan MG, Legare RD, et al: Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 23:166-175, 1999
22. Harada H, Harada Y, Niimi H, et al: High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 103:2316-2324, 2004
23. Chen CY, Lin LI, Tang JL, et al: RUNX1 gene mutation in primary myelodysplastic syndrome: The mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br J Haematol 139:405-414, 2007
24. Preudhomme C, Warot-Loze D, Roumier C, et al: High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2αB gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood 96:2862-2869, 2000
25. Roumier C, Eclache V, Imbert M, et al: M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: A report of 59 cases by the Groupe Français d'Hé matologie Cellulaire (GFHC) and the Groupe Français de Cytogénétique Hématologique (GFCH). Blood 101:1277-1283, 2003
26. Matsuno N, Osato M, Yamashita N, et al: Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype. Leukemia 17:2492-2499, 2003
27. Silva FP, Morolli B, Storlazzi CT, et al: Identification of RUNX1/AML1 as a classical tumor suppressor gene. Oncogene 22:538-547, 2003
28. Silva FP, Lind A, Brouwer-Mandema G, et al: Trisomy 13 correlates with RUNX1 mutation and increased FLT3 expression in AML-M0 patients. Haematologica 92:1123-1126, 2007
29. Dicker F, Haferlach C, Kern W, et al: Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. Blood 110:1308-1316, 2007
30. Osato M, Asou N, Abdalla E, et al: Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2αB gene associated with myeloblastic leukemias. Blood 93:1817-1824, 1999
31. Schnittger S, Dicker F, Kern W, et al: RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood 117:2348-2357, 2011
32. Gaidzik VI, Bullinger L, Schlenk RF, et al: RUNX1 mutations in acute myeloid leukemia: Results from a comprehensive genetic and clinical analysis from the AML Study Group. J Clin Oncol 29:1364-1372, 2011
33. Tang JL, Hou HA, Chen CY, et al: AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: Prognostic implication and interaction with other gene alterations. Blood 114:5352-5361, 2009
34. Langabeer SE, Gale RE, Rollinson SJ, et al: Mutations of the AML1 gene in acute myeloid leukemia of FAB types M0 and M7. Genes Chromosomes Cancer 34:24-32, 2002
35. Mrózek K, Carroll AJ, Maharry K, et al: Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: The Cancer and Leukemia Group B experience. Int J Oncol 33:239-244, 2008
36. Whitman SP, Ruppert AS, Radmacher MD, et al: FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood 111:1552-1559, 2008
37. Caligiuri MA, Strout MP, Schichman SA, et al: Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res 56:1418-1425, 1996
38. Metzeler KH, Becker H, Maharry K, et al: ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood 118:6920-6929, 2011
39. Marcucci G, Metzeler KH, Schwind S, et al: Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol 30:742-750, 2012
40. Garcia JS, Madzo J, Cooper D, et al: Pre-donor evaluation of an HLA matched sibling identifies a novel inherited RUNX1 mutation encoding a missense mutation found outside of the RUNT domain in familial platelet disorder. Blood 116:1116-1117, 2010 (abstr 2709)
41. Georgantas RW 3rd, Tanadve V, Malehorn M, et al: Microarray and serial analysis of gene expression analyses identify known and novel transcripts overexpressed in hematopoietic stem cells. Cancer Res 64:4434-4441, 2004
42. He X, Gonzalez V, Tsang A, et al: Differential gene expression profiling of CD34+ CD133+ umbilical cord blood hematopoietic stem progenitor cells. Stem Cells Dev 14:188-198, 2005
43. Murray LJ, Bruno E, Uchida N, et al: CD109 is expressed on a subpopulation of CD34+ cells enriched in hematopoietic stem and progenitor cells. Exp Hematol 27:1282-1294, 1999
44. Toren A, Bielorai B, Jacob-Hirsch J, et al: CD133-positive hematopoietic stem cell "stemness" genes contain many genes mutated or abnormally expressed in leukemia. Stem Cells 23:1142-1153, 2005
45. Eppert K, Takenaka K, Lechman ER, et al: Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 17:1086-1093, 2011
46. Gentles AJ, Plevritis SK, Majeti R, et al: Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA 304:2706-2715, 2010
47. Santos PM, Borghesi L: Molecular resolution of the B cell landscape. Curr Opin Immunol 23:163-170, 2011
48. Baldus CD, Tanner SM, Ruppert AS, et al: BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: A Cancer and Leukemia Group B study. Blood 102:1613-1618, 2003
49. Langer C, Radmacher MD, Ruppert AS, et al: High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: A Cancer and Leukemia Group B (CALGB) study. Blood 111:5371-5379, 2008
50. Langer C, Marcucci G, Holland KB, et al: Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 27:3198-3204, 2009
51. Büssing I, Slack FJ, Grosshans H: Let-7 microRNAs in development, stem cells and cancer. Trends Mol Med 14:400-409, 2008
52. Fazi F, Rosa A, Fatica A, et al: A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPα regulates human granulopoiesis. Cell 123:819-831, 2005
53. Dixon-McIver A, East P, Mein CA, et al: Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. PLoS One 3:e2141, 2008
54. Schlenk RF, Döhner K, Krauter J, et al: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358: 1909-1918, 2008
55. Osato M: Point mutations in the RUNX1/AML1 gene: Another actor in RUNX leukemia. Oncogene 23:4284-4296, 2004
56. Silva FP, Swagemakers SM, Erpelinck-Verschueren C, et al: Gene expression profiling of minimally differentiated acute myeloid leukemia: M0 is a distinct entity subdivided by RUNX1 mutation status. Blood 114:3001-3007, 2009